Sutro Biopharma, a US-based company that makes synthetic proteins for drugs, has raised $36.5m in its series C round from a consortium including two corporate venturing units.
Led by venture capital (VC) firm Skyline Ventures, the C round included Lilly Ventures and Amgen Ventures from drug companies Eli Lilly and Amgen respectively. The other members of the consortium were VCs SV Life Sciences and Alta Partners.
Armen Shanafelt, a venture partner at Lilly Ventures, has joined Sutro’s board, along with Leon Chen, a partner at Skyline.
Sutro previously raised $23m, including $21m in its series B round in December 2007 from SV and Alta.